These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil. Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123 [TBL] [Abstract][Full Text] [Related]
3. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Yoshikawa R; Kusunoki M; Yanagi H; Noda M; Furuyama JI; Yamamura T; Hashimoto-Tamaoki T Cancer Res; 2001 Feb; 61(3):1029-37. PubMed ID: 11221829 [TBL] [Abstract][Full Text] [Related]
5. Chronopharmacokinetics of oral tegafur and uracil in colorectal cancer patients. Etienne-Grimaldi MC; Cardot JM; François E; Renée N; Douillard JY; Gamelin E; Milano G Clin Pharmacol Ther; 2008 Mar; 83(3):413-5. PubMed ID: 17637782 [TBL] [Abstract][Full Text] [Related]
6. Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low-dose leucovorin for patients with gastric cancer. Ichikura T; Tomimatsu S; Okusa Y; Yahara T; Uefuji K; Tamakuma S Cancer Chemother Pharmacol; 1996; 38(5):401-5. PubMed ID: 8765432 [TBL] [Abstract][Full Text] [Related]
7. The oral fluoropyrimidines in cancer chemotherapy. Lamont EB; Schilsky RL Clin Cancer Res; 1999 Sep; 5(9):2289-96. PubMed ID: 10499595 [TBL] [Abstract][Full Text] [Related]
8. [5-FU pharmacokinetic study of 5-FU hepato-arterial infusion with oral UFT]. Maruyama M; Ebuchi M; Nagahama T; Takashima I; Hasegawa K; Ochiai T; Natui S Gan To Kagaku Ryoho; 2002 Nov; 29(12):2109-11. PubMed ID: 12484014 [TBL] [Abstract][Full Text] [Related]
9. [Effects of combination chemotherapy with topical application of 5-FU ointment to mice's tongue and UFT]. Tateishi A; Sakaki Y; Kameyama Y; Hara I; Yamada N Gan To Kagaku Ryoho; 1990 Sep; 17(9):1877-85. PubMed ID: 2118335 [TBL] [Abstract][Full Text] [Related]
10. Comparative pharmacology of oral fluoropyrimidines: a focus on pharmacokinetics, pharmacodynamics and pharmacomodulation. Milano G; Ferrero JM; François E Br J Cancer; 2004 Aug; 91(4):613-7. PubMed ID: 15280932 [TBL] [Abstract][Full Text] [Related]
11. Expression of dihydropyrimidine dehydrogenase in cancer cells but not in stromal cells predicts the efficacy of fluorouracil treatment in patients with gastric carcinoma. Hisamitsu K; Tsujitani S; Yamaguchi K; Fukuda K; Konishi I; Kaibara N Anticancer Res; 2004; 24(4):2495-501. PubMed ID: 15330204 [TBL] [Abstract][Full Text] [Related]
12. Development of a pharmacokinetic model to optimize the dosage regimen of TS-1, a combination preparation of tegafur, gimeracil and oteracil potassium. Inoue S; Ohtani H; Tsujimoto M; Hori S; Sawada Y Drug Metab Pharmacokinet; 2007 Jun; 22(3):162-8. PubMed ID: 17603216 [TBL] [Abstract][Full Text] [Related]
13. UFT and leucovorin: a review of its clinical development and therapeutic potential in the oral treatment of cancer. Hoff PM; Pazdur R; Benner SE; Canetta R Anticancer Drugs; 1998 Jul; 9(6):479-90. PubMed ID: 9877235 [TBL] [Abstract][Full Text] [Related]
14. The use of thymidylate synthase inhibitors in the treatment of advanced colorectal cancer: current status. Papamichael D Stem Cells; 2000; 18(3):166-75. PubMed ID: 10840069 [TBL] [Abstract][Full Text] [Related]
15. Oral therapy for colorectal cancer: how to choose. Damjanov N; Meropol NJ Oncology (Williston Park); 2000 Jun; 14(6):799-807; discussion 807-8, 813-4,. PubMed ID: 10887632 [TBL] [Abstract][Full Text] [Related]
16. [Studies on 5-FU concentration in serum and prostate cancer tissue after oral administration of UFT]. Shinoda I; Takahashi Y; Takeuchi T; Kuriyama M; Ban Y; Kawada Y; Ito Y; Yamamoto N; Maeda S; Tada K Hinyokika Kiyo; 1991 Jul; 37(7):711-5. PubMed ID: 1927771 [TBL] [Abstract][Full Text] [Related]
17. [A study of urinary tegafur, 5-fluorouracil (5-FU) and uracil concentrations in the cases of gastric carcinoma for the confirmation of drug-taking compliance after UFT oral administration]. Ohsawa S; Kondo Y; Shiroto H; Masuko H; Fukushima T; Kataoka A; Ohmori K; Sawaguchi Y; Baba E; Takahashi T Gan To Kagaku Ryoho; 1992 Nov; 19(13):2189-93. PubMed ID: 1444485 [TBL] [Abstract][Full Text] [Related]
18. [Antitumor activity and function of S-1, a new oral tegafur-based formulation]. Fukushima M Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():19-26. PubMed ID: 16897968 [TBL] [Abstract][Full Text] [Related]
19. [Study on the concentrations of 5-fluorouracil (5-FU), tegafur (ET) and uracil in bile: comparison of UFT or FT]. Tomita T; Tajima T; Ishibashi M; Tagaya N; Aoki H; Itoh S; Kadowaki A; Kogure H; Tajima Y Gan To Kagaku Ryoho; 1989 Dec; 16(12):3755-62. PubMed ID: 2512859 [TBL] [Abstract][Full Text] [Related]
20. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cao S; Baccanari DP; Joyner SS; Davis ST; Rustum YM; Spector T Cancer Res; 1995 Dec; 55(24):6227-30. PubMed ID: 8521418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]